Hand-foot skin reaction predicts treatment outcome of pazopanib in patients with metastatic soft tissue sarcoma: A multicenter study in the Asian population-Reference-Cited by-同舟云学术

Hand-foot skin reaction predicts treatment outcome of pazopanib in patients with metastatic soft tissue sarcoma: A multicenter study in the Asian population

Published:2018-06-13 Issue:4 Volume:14 Page:353-360
ISSN:1743-7555
Container-title:Asia-Pacific Journal of Clinical Oncology
language:en
Short-container-title:Asia-Pac J Clin Oncol

Author:

Huang Pei-Wei¹^ORCID,Chou Wen-Chi¹^ORCID,Shen Wen-Chi¹,Hung Chia-Yen¹²^ORCID,Huang Kuan-Gen³^ORCID,Su Yu-Li⁴^ORCID,Lu Chang-Hsien⁵,Liu Chien-Ting⁴,Chang Yueh-Shih⁶,Liau Chi-Ting¹^ORCID

Affiliation:

1. Division of Hematology-Oncology; Chang Gung Memorial Hospital at Linkou; Chang Gung University College of Medicine; Tao-Yuan Taiwan

2. Department of Hema-Oncology; Division of Internal Medicine; Mackay Memorial Hospital; Taipei Taiwan

3. Division of Gynecologic Oncology; Chang Gung Memorial Hospital at Linkou; Chang Gung University College of Medicine; Tao-Yuan Taiwan

4. Division of Hematology-Oncology; Chang Gung Memorial Hospital; Kaohsiung Taiwan

5. Division of Hematology-Oncology; Chang Gung Memorial Hospital; Chiayi Taiwan

6. Division of Hematology-Oncology; Chang Gung Memorial Hospital; Keelung Taiwan

Publisher

Wiley

Subject

Oncology,General Medicine

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/ajco.13029/fullpdf

Reference25 articles.

1. Soft-tissue sarcomas in adults;Clark;N Engl J Med,2005

2. Doxorubicin alone versus intensified doxorubicin plus ifosfamide for first-line treatment of advanced or metastatic soft-tissue sarcoma: a randomised controlled phase 3 trial;Judson;Lancet Oncol,2014

3. Gemcitabine and docetaxel versus doxorubicin as first-line treatment in previously untreated advanced unresectable or metastatic soft-tissue sarcomas (GeDDiS): a randomised controlled phase 3 trial;Seddon;Lancet Oncol,2017

4. Pazopanib, a multikinase angiogenesis inhibitor, in patients with relapsed or refractory advanced soft tissue sarcoma: a phase II study from the European organisation for research and treatment of cancer-soft tissue and bone sarcoma group (EORTC Study 62043);Sleijfer;J Clin Oncol,2009

5. Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trial;der Graaf;Lancet,2012

Cited by 10 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Real-world data on the management of pazopanib-induced liver toxicity in routine care of renal cell cancer and soft tissue sarcoma patients;Cancer Chemotherapy and Pharmacology;2023-12-17

2. Metastatik Renal Hücreli Kanser ve Metastatik Sarkom Tedavisi Sırasında Gelişen Pazopanib İlişkili Makrositoz’un Klinik Önemi;Akdeniz Medical Journal;2023-08-22

3. Real-world outcomes of pazopanib in metastatic soft tissue sarcoma: a retrospective Turkish oncology group (TOG) study;Journal of Cancer Research and Clinical Oncology;2023-04-17

4. Efficacy and safety of apatinib in advanced refractory soft tissue sarcoma and association with histologic subtypes: a multicenter retrospective study;Annals of Translational Medicine;2022-09

5. Real-World Outcome and Prognostic Factors of Pazopanib in Advanced Soft Tissue Sarcoma;Cancer Management and Research;2021-08